AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Rhea-AI Summary

AbbVie (NYSE:ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Company management will join a fireside chat at 9:40 a.m. Central time.

A live audio webcast and later archived replay will be available on AbbVie's investor relations website.

News Market Reaction – ABBV

+1.16%

+1.16% Session close to close

In the Jun 2 session, ABBV gained 1.16%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights AbbVie’s participation in a major healthcare investor conference, with ...

Analysis

This announcement highlights AbbVie’s participation in a major healthcare investor conference, with management scheduled for a fireside chat on June 9, 2026 at 9:40 a.m. Central. It adds to a period of active news flow that recently included regulatory approvals and positive opinions in oncology, hepatitis C, and aesthetics. Investors may focus on any incremental strategic or pipeline commentary from the webcast, especially given ABBV’s price trading below its 200‑day moving average of $219.64.

Key Figures

Conference edition: 47th Conference date: June 9, 2026 Presentation time: 9:40 a.m. Central

3 metrics

Conference edition 47th Goldman Sachs Annual Global Healthcare Conference

Conference date June 9, 2026 Scheduled presentation date

Presentation time 9:40 a.m. Central Fireside chat start time

Historical Context

5 past events · Latest: May 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 29	EU label expansion	Positive	-0.4%	European Commission authorized expanded VENCLYXTO label for first-line CLL combinations.
May 27	FDA approval	Positive	+1.5%	U.S. FDA approved DECNUPAZ for adult BPDCN based on CADENZA trial data.
May 22	CHMP opinion	Positive	+0.6%	Positive CHMP opinion for MAVIRET in acute hepatitis C in adults and children.
May 21	Oncology data update	Positive	+0.6%	ASCO 2026 presentations on next‑generation oncology pipeline across solid and blood cancers.
May 21	Aesthetics CHMP opinion	Positive	+0.6%	Positive CHMP opinion for Boey to treat moderate to severe glabellar lines in adults.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive regulatory and clinical updates generally saw modestly positive price alignment, with one small divergence on an EU label expansion.

Recent Company History

Over the last few weeks, AbbVie reported several positive regulatory and clinical milestones. On May 21–22, it highlighted new oncology pipeline data at ASCO 2026 and a positive CHMP opinion for MAVIRET in acute hepatitis C, each followed by about 0.56% gains. A May 27 U.S. FDA approval for DECNUPAZ in BPDCN coincided with a 1.5% rise. By contrast, a May 29 VENCLYXTO label expansion in Europe saw a small -0.42% pullback. Today’s conference appearance fits into an active period of external visibility.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. Management will participate in a fireside chat at 9:40 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Media: Marianne Ostrogorski   (224) 240-6336 marianne.ostrogorski@abbvie.com

Investors: Liz Shea (847) 935-2211 liz.shea@abbvie.com

 

View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference-302787501.html

SOURCE AbbVie

FAQ

When will AbbVie (NYSE:ABBV) present at the Goldman Sachs 47th Annual Global Healthcare Conference?

AbbVie will present on June 9, 2026, at the Goldman Sachs 47th Annual Global Healthcare Conference. According to AbbVie, management will participate in a fireside chat at 9:40 a.m. Central time.

What time is AbbVie's fireside chat at the Goldman Sachs 2026 healthcare conference?

AbbVie's fireside chat is scheduled for 9:40 a.m. Central time on June 9, 2026. According to AbbVie, management will participate as part of the Goldman Sachs 47th Annual Global Healthcare Conference.

How can investors listen to AbbVie's presentation at the Goldman Sachs healthcare conference?

Investors can listen via a live audio webcast on AbbVie's investor relations website at investors.abbvie.com. According to AbbVie, an archived edition of the session will also be available later that day.

Will a replay of AbbVie's June 9, 2026 conference presentation be available?

Yes, a replay will be available. According to AbbVie, an archived edition of the Goldman Sachs 47th Annual Global Healthcare Conference fireside chat will be accessible on its investor relations website later that day.

Where is AbbVie's investor relations website for the Goldman Sachs conference webcast?

AbbVie's investor relations website is located at investors.abbvie.com. According to AbbVie, this site will host the live audio webcast and archived replay of the June 9, 2026 Goldman Sachs healthcare conference session.